Biogen's monoclonal antibody felzartamab wins first global approval in China

Biogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lenalidomide and the corticosteroid dexamethasone. Yesterday's approval comes just ...